AI Article Synopsis
- Erythropoietin (EPO) has both blood-forming (hematopoietic) and tissue-protecting functions, which are believed to occur through different receptor interactions.
- Researchers developed selective ligands that distinguish between the different effects of EPO at cellular and animal levels.
- Certain modified forms of EPO, like Carbamylated EPO (CEPO), do not trigger blood formation but still offer strong protective benefits against various neurological conditions, showing effectiveness similar to regular EPO.
Article Abstract
Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype-selective ligands allowing the separation of EPO's bioactivities at the cellular level and in animals. Carbamylated EPO (CEPO) or certain EPO mutants did not bind to the classical EPO receptor (EPOR) and did not show any hematopoietic activity in human cell signaling assays or upon chronic dosing in different animal species. Nevertheless, CEPO and various nonhematopoietic mutants were cytoprotective in vitro and conferred neuroprotection against stroke, spinal cord compression, diabetic neuropathy, and experimental autoimmune encephalomyelitis at a potency and efficacy comparable to EPO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.1098313 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!